Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment

　　I.Standard Treatment Duration:Science-Based Protocol

　　Pretomanid,combined with Bedaquiline and Linezolid(BPaL regimen),is exclusively for XDR-TB or MDR-TB.The standard course is 6-9 months,adjusted based on sputum conversion.In rare complex cases,extension to 12-15 months may occur,but a 3-year course significantly exceeds guidelines and warrants caution.

　　II.Risks of Prolonged Use:Limited Data,Elevated Hazards

　　Clinical trials(e.g.,Nix-TB)support only 6-9 months of Pretomanid.Three-year use lacks safety evidence,posing risks such as irreversible peripheral neuropathy from Linezolid,cumulative hepatotoxicity,myelosuppression,escalating drug resistance,and microbiome disruption.Continuation beyond recommended duration requires reevaluation.

　　III.Causes of 3-Year Treatment

　　Potential factors include:1)Misdiagnosis or complex conditions(HIV co-infection,extensive resistance,severe lung damage)leading to repetitive cycles;2)Patient-initiated extension without medical supervision;3)TB relapse.In all scenarios,risks outweigh benefits.

　　IV.Response Protocol:Expert Assessment&Timely Adjustment

　　Patients on 3-year Pretomanid must undergo immediate evaluation at a specialized TB center:sputum culture,drug sensitivity tests,chest CT,liver/kidney function tests,nerve conduction studies.If no active disease is detected,discontinue BPaL;if treatment remains necessary,switch to a new regimen due to potential resistance development.

　　V.Post-Treatment Monitoring:Long-term Follow-up&Symptomatic Management

　　Follow-up for at least 12 months after discontinuation to monitor relapse and organ function.Treat neuropathy with vitamin B12 supplementation or analgesics as needed.

　　VI.Conclusion:Evidence-Driven Treatment,Avoiding Overuse

　　A 3-year Pretomanid course is non-standard and high-risk.Seek specialist consultation for drug sensitivity analysis and clinical reassessment to ensure safe and effective treatment.